BiotechTube
Kyowa Hakko Kirin

Kyowa Hakko Kirin

4151
New York, United States· Est.
kyowakirin.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

Kyowa Kirin is a publicly traded, global specialty pharma leader with deep roots in Japanese innovation, strategically focused on high-need therapeutic areas including bone & mineral disorders, hematologic malignancies, and rare diseases. Its success is built on proprietary technology platforms like POTELLIGENT® for enhanced antibody therapeutics and the Orchard Therapeutics acquisition for hematopoietic stem cell gene therapy. The company's strategy combines internal R&D excellence with strategic business development to build a sustainable pipeline of transformative medicines, aiming to deliver its 'Vision 2030' of creating life-changing value for patients worldwide.

Bone & MineralHematologic MalignanciesRare Diseases

Technology Platform

Proprietary antibody engineering (POTELLIGENT/COMPLEGENT) for enhanced ADCC/CDC and a hematopoietic stem cell gene therapy (HSC-GT) platform for ex vivo gene correction of rare genetic disorders.

Funding History

2
Total raised:$150M
Series B$100M
Series A$50M

Opportunities

The successful scaling of its gene therapy franchise represents a multi-billion dollar opportunity in ultra-rare diseases.
Geographic expansion of its specialty portfolio in North America and Europe provides near-term revenue growth.
Leveraging its antibody platform for next-generation constructs (e.g., bispecifics) can expand its oncology footprint.

Risk Factors

High dependence on successful commercialization and reimbursement of ultra-expensive gene therapies.
Clinical and regulatory setbacks in the late-stage pipeline could impair growth.
Intensifying competition and pricing pressure across all core therapeutic areas.

Competitive Landscape

Operates as a focused specialist against both large pharma and agile biotechs. In gene therapy, competes with Bluebird Bio, CSL Behring, and others on clinical outcomes and market access. In hematology/oncology and bone disorders, competes on mechanism differentiation and deep clinical data in niche indications.

More companies in Biologics / Biosimilars →More companies in United States →